Is rimonabant efficacious and safe in the treatment of obesity?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 15, 2008, Pages 2727-2731

  Doggrell, Sheila A ^a  

^a RMIT University Bundoora West Campus   (Australia)

Author keywords

Atherosclerosis; Clinical trials; Obesity; Rimonabant; RIO; STRADIVARIUS; Weight loss

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PLACEBO; RIMONABANT; TICLOPIDINE;

AGITATION; ANXIETY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; AUTOMUTILATION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; INTRAVASCULAR ULTRASOUND; LOW CALORY DIET; MAJOR DEPRESSION; MENTAL DISEASE; METABOLIC SYNDROME X; NAUSEA; OBESITY; PATIENT COUNSELING; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PLACEBOS; PYRAZOLES; TREATMENT OUTCOME;

EID: 55249102956     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.15.2727     Document Type: Article

References (13)

1. Peters A, Barendregt JJ, Willenkens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32
2. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-9
3. Van Gaal LF, Rissanen AM, Ziegler O, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1388-97
4. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A Randomized Controlled Trial. JAMA 2006;295:761-75
5. Deprés JP, Golay A, Sjöstóm L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
6. Scheen AJ, Finer N, Hollander P, et al. For the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72
7. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-43
8. US Food and Drug Administration Advisory Committee. FDA Briefing Document. NDA 21-888 Zimulti (rimonabant) Tablets, 20 mg Sanofi Aventis Advisory Committee - 13 June 2007 Available from: www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf [Accessed on 7th July 2008]
9. Van Gaal L, Pi-Sunyer X, Deprés JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31(Suppl 2):S229-40
10. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease - the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-60
11. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's paediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164:1035-43
12. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant. Available from: http://clinicaltrials.gov/ct2/show/NCT00228176 [Accessed on 7th July 2008]
13. Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). Available from: http://clinicaltrials.gov/ct/ show/NCT00263042 [Accessed on 7th July 2008]